Research into the therapeutic potential of psychedelics is underway at University of Washington in Seattle. Dr. Anthony Back, co-director of the University’s Center for Excellence in Palliative Care, will lead a trial exploring the effects of psilocybin to alleviate the mental health burden experienced by frontline healthcare workers over the course of COVID-19. This trial is sponsored in part by Cybin and will use their psilocybin formulation.
With a motion underway to legalize psilocybin therapy in Washington State, more research will likely take place at UW soon.
Company Information
University of Washington in Seattle Website
Founded
January, 1970
Operational
Yes
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates